Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial. Issue 8 (25th August 2022)

• Record Type: Journal Article
• Authors: Yuan, Jing-Jing; Ding, Jian-Wu; Li, Jin-Wei; Hu, Rong-Huan; Gong, Dan; Hu, Jia-Li; Zhu, Kai-Bin; Liu, Yan; Ding, Yu-Hai; Wei, Jia-Wang; Zeng, Jian-Lun; Lu, Zhi-Bing; Yin, Wei-Hua; Ai, Su-Fen; Zha, Guo-Hua; Zhang, Zhi-Lin; Zou, Rui; Zeng, Lei
• Is Part Of: BMJ open. Volume 12:Issue 8(2022)
• Publication Date: 2022-08-25
• Subjects: chemotherapy -- radiotherapy -- head & neck tumours; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2021-051594
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Epidermal growth factor receptor (EGFR) is a therapeutic target in nasopharyngeal carcinoma (NPC). The optimal combined modality of optimal combined modality of anti-­EGFR monoclonal antibodies, induction chemotherapy (ICT), concurrent chemotherapy and radiotherapy for NPC remains poorly defined. None of previous studies have developed subsequent treatment strategies on the basis of stratification according to the efficacy following ICT plus anti-EGFR mAbs. This study aims to increase treatment intensity for patients with poor efficacy of ICT and reduce treatment toxicity for patients with favourable efficacy of ICT by assessing whether the efficacy of this treatment regimen is non-inferior to ICT plus concurrent chemoradiotherapy (historic controls). Introduction: Methods and analysis: Pathology-confirmed WHO type II/III NPC patients at clinical stage III–IVA (eighth American Joint Committee on Cancer/Union for International Cancer Control staging system) will be included in the study. They will receive ICT plus nimotuzumab (NTZ), followed by radiotherapy plus NTZ or concurrent chemoradiotherapy plus NTZ (stratified based on the efficacy of ICT plus NTZ). The primary endpoint is 3-year failure-free survival rate; while the secondary endpoints are 3-year overall survival rate, distant metastasis-free survival rate and locoregional recurrence-free survival rate, and short-term remission rate of tumour and treatment toxicity. Ethics and dissemination: The study protocol has been approved by the Ethics Committee of the Second Affiliated Hospital of Nanchang University. Our findings will be disseminated in a peer-reviewed journal. Implementation strategies are in place to ensure privacy and confidentiality of participants. Trial registration number: ChiCTR2000041139.